Value Adjusted for Debt and Cash: uniQure Pharma (QURE)

Stable royalties from therapy licensing support the margins of uniQure N.V. (QURE), despite capital-intensive research. The business is insulated from market cycles and seasonality, relying on test results and patents, although it remains sensitive to venture capital. This chart reflects a current market valuation of 1464.20. uniQure N.V. (QURE) develops treatments for hemophilia and Huntington's disease, utilizing its own plants to maintain full control over drug production.

To assess the valuation of the uniQure N.V. (QURE) gene therapy ecosystem and its modular AAV platform, utilize the enterprise value chart. This indicator determines the actual cost of acquiring the asset in real-time. The calculation is based on the sum of market capitalization and debt, minus cash and cash equivalents. This metric reveals valuation gaps critical for fundamental analysis, serving as a key tool for evaluating high-tech biotechnology companies.